Alcon(US:ALC)2026-02-24 21:35Financial Performance - Net sales for Q4 2025 were $2.7 billion, a 9% increase from $2.5 billion in Q4 2024, with full-year net sales reaching $10.3 billion, up 5% from $9.8 billion[4]. - Gross profit for Q4 2025 was $1.5 billion, a 9% increase year-over-year, with a gross margin of 56.1% compared to 55.9% in Q4 2024[10]. - Operating income for Q4 2025 decreased by 21% to $313 million, with an operating margin of 11.6%, down from 15.9% in the prior year[11]. - Net income attributable to shareholders for Q4 2025 was $217 million, a 24% decrease from $284 million in Q4 2024, resulting in basic and diluted earnings per share of $0.44[26]. - Net income for 2025 was $980 million, a decrease from $1.0 billion in the prior year, with basic and diluted earnings per share at $1.99 and $1.98, respectively, down from $2.06 and $2.05[31]. - Total comprehensive income for the twelve months ended December 31, 2025, increased to $1,189 million, up 25% from $952 million in 2024[55]. - Operating income for the twelve months ended December 31, 2025, was $1,360 million, compared to $1,413 million in 2024, reflecting a decrease of 3.7%[91]. Segment Performance - Surgical segment net sales for Q4 2025 were $1.5 billion, a 9% increase, while Vision Care segment net sales were $1.2 billion, a 10% increase[5][6]. - Surgical segment contribution for Q4 2025 was $389 million, a 12% increase, while Vision Care segment contribution decreased by 10% to $235 million[15][16]. - Surgical segment net sales amounted to $5.751 billion in 2025, up from $5.522 billion in 2024, driven by a 7.5% increase in consumables sales[88]. - Vision Care segment net sales increased to $4.568 billion in 2025, compared to $4.314 billion in 2024, with contact lens sales contributing $2.770 billion[88]. Expenses and Costs - Research and development expenses increased by 18% to $273 million in Q4 2025, reflecting investments in new product launches and acquisitions[10]. - Interest expense for Q4 2025 was $53 million, up from $48 million in Q4 2024, primarily due to higher interest from long-term liabilities[22]. - Tax expense for Q4 2025 was $47 million, with an average tax rate of 17.8%, down from 18.6% in the prior year[25]. - Research and development expenses for the twelve months ended December 31, 2025, totaled $990 million, up from $876 million in 2024, indicating a 13% increase[91]. - The company recognized impairment testing for goodwill and intangible assets, which may lead to significant impairment charges in the future[72]. Cash Flow and Assets - Net cash flows from operating activities increased to $2.3 billion in 2025 from $2.1 billion in the prior year, driven by higher sales and lower taxes paid[32]. - Total non-current assets rose to $25.1 billion as of December 31, 2025, an increase of $1.1 billion compared to the previous year, primarily due to acquisitions and capital expenditures[39]. - Cash and cash equivalents decreased to $1,527 million as of December 31, 2025, down from $1,676 million in 2024, a decline of 8.9%[63]. - Total assets as of December 31, 2025, reached $31,555 million, representing a growth of 3.7% from $30,347 million in 2024[59]. - Total current liabilities increased to $3.0 billion as of December 31, 2025, up by $771 million from the prior year, mainly due to an increase in financial debts and trade payables[42]. Shareholder Returns - The company authorized a share repurchase program of up to $750 million, completing the repurchase of 9.3 million shares for the total amount[49]. - Dividends paid to shareholders increased to $168 million in 2025, compared to $130 million in 2024, reflecting a growth of 29.2%[63]. - The company proposed a dividend of CHF 0.28 per share, resulting in a total payout of $166 million in May 2025[95]. Acquisitions and Divestitures - Alcon acquired LumiThera, Inc. for $124 million, resulting in $38 million of goodwill, enhancing its Surgical portfolio with the Valeda device[75]. - The acquisition of a majority interest in Aurion Biotech, Inc. for $522 million resulted in $175 million of goodwill, supporting Alcon's ophthalmic pharmaceutical expansion[76]. - Alcon's acquisition of Cylite Pty Ltd. for $72 million led to $90 million of goodwill, complementing its cataract surgical portfolio[77]. - The acquisition of BELKIN Vision Ltd. was finalized for $61 million, with goodwill recognized at $20 million[167]. - Alcon divested its rights in China for Bion Tears and Tears Naturale, receiving up-front consideration of $116 million and potential additional amounts up to $50 million upon achieving certain commercial milestones[174]. Financial Position and Liabilities - Total financial debts as of December 31, 2025, amounted to $4,737 million, an increase from $4,643 million in 2024[107]. - Financial debts decreased to $4,162 million in 2025 from $4,538 million in 2024, a reduction of 8.3%[59]. - Contingent consideration liabilities rose to $(169) million in 2025 from $(96) million in 2024, indicating a 76.0% increase[121]. - The maximum remaining potential payments related to contingent consideration from business combinations is estimated at $1.4 billion, with probabilities of success for various milestones ranging from 0% to 95%[122]. Future Outlook - The company plans to continue investing in new product launches and research and development to drive future growth[11]. - Alcon is evaluating the impact of adopting IFRS 18, which is expected to enhance financial statement comparability and transparency starting January 1, 2027[73]. - Alcon announced efficiency measures with an estimated implementation cost of approximately $150 million, expected to be completed in 2026[183].